Longitudinal <sup>1</sup> H and <sup>129</sup> Xe Lung MRI in Patients With Post‐COVID Residual Lung Abnormalities

ABSTRACT Background It is unclear how lung function may recover in patients with residual lung abnormalities (RLAs) following COVID‐19 pneumonia. Purpose To evaluate lung function trends over time in patients with RLAs following hospitalization due to COVID‐19. Study Type Prospective, multicenter longitudinal cohort study. Population Twenty‐four participants hospitalized due to COVID‐19 with RLAs identified on CT ≥ 3 months postdischarge (median [IQR] age 69 (15) years; 3 female) underwent at least one MRI at 6 months ( n = 16), 1 year ( n = 19), or 2 years ( n = 14). Field Strength/Sequence 1.5 T. Dynamic contrast enhanced (DCE) 3D spoiled gradient echo, 129 Xe steady state free precession (ventilation), 129 Xe 3D spoiled gradient echo multiple b ‐value (diffusion‐weighted), 129 Xe 4‐echo flyback 3D radial (dissolved phase). Assessment Pulmonary blood flow, volume, and mean transit time (MTT) were calculated from DCE MRI. The fraction of 129 Xe signal in the red blood cells to membrane (RBC:M) was calculated from the dissolved phase 129 Xe acquisition. Ventilation defect percentage (VDP) was calculated from the 129 Xe ventilation acquisition. Mean diffusive length scale (Lm D ) was calculated from the 129 Xe diffusion‐weighted acquisition. Statistical Tests Changes in metrics with time and associations between metrics were assessed using mixed‐effect linear regression. Correlations were tested using Spearman's correlation coefficient. Regional differences were assessed using a Friedman's test with a Bonferroni adjustment. p &lt; 0.05 was considered significant. Results Pulmonary blood flow and MTT improved significantly over time (MTT: 6 months, 15.3 (IQR, 2.0); 1 year, 15.6 (1.4); 2 years, 15.0 (5.3); pulmonary blood flow: 6 months, 75.4 (IQR, 22.0); 1 year, 83.2 (47.4); 2 years, 107.3 (51.1)). RBC:M z ‐score was low at all three visits (6 months, −2.85 (0.98); 1 year, −2.44 (1.34); 2 years, −2.60 (1.39)), with no improvement with time ( p = 0.993). VDP and Lm D did not significantly change with time (VDP: p = 0.100; Lm D : p = 0.166). Data Conclusion Improvements in lung perfusion were measured; however, there was no corresponding enhancement in RBC:M. Evidence Level Level 2. Technical Efficacy Stage 3.

Authors

Institutions

Publication Details

Journal
Journal of Magnetic Resonance Imaging
Published
2026-05-28
DOI
https://doi.org/10.1002/jmri.70368
Primary Topic
Atomic and Subatomic Physics Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Longitudinal 1 H and 129 Xe Lung MRI in Patients With Post‐COVID Residual Lung Abnormalities

Amanda Goodwin, Ho‐Fung Chan, Thomas Meersmann, Smitha Rajaram et al.
Journal of Magnetic Resonance Imaging
Atomic and Subatomic Physics Research
article

Longitudinal 1 H and 129 Xe Lung MRI in Patients With Post‐COVID Residual Lung Abnormalities

Amanda Goodwin, Ho‐Fung Chan, Thomas Meersmann, Smitha Rajaram, Gísli Jenkins, Paul Collini, Gary Mills, S Strickland, J Brooke, Megan Plowright, Graham Norquay, Kher Lik Ng, I Hall, J Ball, Rod Lawson, Laura Saunders, Ling‐Pei Ho, J Blaikley, Jody Bray, Lotta Gustafsson, Alberto Biancardi, Arthur Harrison, Zoë Gabriel, Andrew J. Swift, A A Roger Thompson, James T. Grist, Thomas Newman, S Stanel, I Stewart, C E Bolton, Helen Marshall, Galina E. Pavlovskaya, Guilhem J. Collier, Neil J. Stewart, Lily M. Pearce, Laurie J. Smith, Jim M. Wild, Paul J. C. Hughes, Kevin M. Johnson, Joseph Jacob, Fergus Gleeson
article en

Abstract

ABSTRACT Background It is unclear how lung function may recover in patients with residual lung abnormalities (RLAs) following COVID‐19 pneumonia. Purpose To evaluate lung function trends over time in patients with RLAs following hospitalization due to COVID‐19. Study Type Prospective, multicenter longitudinal cohort study. Population Twenty‐four participants hospitalized due to COVID‐19 with RLAs identified on CT ≥ 3 months postdischarge (median [IQR] age 69 (15) years; 3 female) underwent at least one MRI at 6 months ( n = 16), 1 year ( n = 19), or 2 years ( n = 14). Field Strength/Sequence 1.5 T. Dynamic contrast enhanced (DCE) 3D spoiled gradient echo, 129 Xe steady state free precession (ventilation), 129 Xe 3D spoiled gradient echo multiple b ‐value (diffusion‐weighted), 129 Xe 4‐echo flyback 3D radial (dissolved phase). Assessment Pulmonary blood flow, volume, and mean transit time (MTT) were calculated from DCE MRI. The fraction of 129 Xe signal in the red blood cells to membrane (RBC:M) was calculated from the dissolved phase 129 Xe acquisition. Ventilation defect percentage (VDP) was calculated from the 129 Xe ventilation acquisition. Mean diffusive length scale (Lm D ) was calculated from the 129 Xe diffusion‐weighted acquisition. Statistical Tests Changes in metrics with time and associations between metrics were assessed using mixed‐effect linear regression. Correlations were tested using Spearman's correlation coefficient. Regional differences were assessed using a Friedman's test with a Bonferroni adjustment. p &lt; 0.05 was considered significant. Results Pulmonary blood flow and MTT improved significantly over time (MTT: 6 months, 15.3 (IQR, 2.0); 1 year, 15.6 (1.4); 2 years, 15.0 (5.3); pulmonary blood flow: 6 months, 75.4 (IQR, 22.0); 1 year, 83.2 (47.4); 2 years, 107.3 (51.1)). RBC:M z ‐score was low at all three visits (6 months, −2.85 (0.98); 1 year, −2.44 (1.34); 2 years, −2.60 (1.39)), with no improvement with time ( p = 0.993). VDP and Lm D did not significantly change with time (VDP: p = 0.100; Lm D : p = 0.166). Data Conclusion Improvements in lung perfusion were measured; however, there was no corresponding enhancement in RBC:M. Evidence Level Level 2. Technical Efficacy Stage 3.

Journal of Magnetic Resonance Imaging
University of Wisconsin–Madison (US), University of Nottingham Ningbo China (CN), University of Manchester (GB), University of Oxford (GB), Madison Group (United States) (US), Sheffield Teaching Hospitals NHS Foundation Trust (GB), Systems, Applications & Products in Data Processing (United Kingdom) (GB), Oxford BioMedica (United Kingdom) (GB), Nottingham Biomedical Research Centre (GB), Oxford University Hospitals NHS Trust (GB), Insigneo (GB), University College London (GB), Imperial College London (GB), University of Sheffield (GB)
Good health and well-being
Openalex Percentile: Top 5%
Atomic and Subatomic Physics Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.